Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Tax Provisions (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Tax Provisions for 16 consecutive years, with $97000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Tax Provisions fell 67.67% to $97000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$9000.0, a 101.4% decrease, with the full-year FY2024 number at $430000.0, down 31.85% from a year prior.
  • Tax Provisions was $97000.0 for Q3 2025 at Harvard Bioscience, up from $74000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $986000.0 in Q2 2022 to a low of -$1.3 million in Q3 2022.
  • A 5-year average of $21823.5 and a median of $97000.0 in 2025 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 544.14% in 2022; the steepest drop was 697.67% in 2022.
  • Harvard Bioscience's Tax Provisions stood at $541000.0 in 2021, then surged by 36.23% to $737000.0 in 2022, then fell by 27.95% to $531000.0 in 2023, then crashed by 39.74% to $320000.0 in 2024, then crashed by 69.69% to $97000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Tax Provisions are $97000.0 (Q3 2025), $74000.0 (Q2 2025), and -$500000.0 (Q1 2025).